Therapeutic options for cutaneous leishmaniasis. 2007

Vikram K Mahajan, and Nand Lal Sharma
Department of Dermatology, Venereology & Leprosy, Indira Gandhi Medical College, Shimla, India.

BACKGROUND Cutaneous leishmaniasis occurs worldwide in both old and new world countries with their own endemic foci. Many of those infected often experience a delay in diagnosis and inappropriate treatment. OBJECTIVE To review the literature in terms of the various treatment options described for cutaneous leishmaniasis. METHODS Literature on the treatment of cutaneous leishmaniasis retrieved by searching Index Medicus, PubMed and IndMed were reviewed. CONCLUSIONS Review reveals no uniform pattern or definite guidelines for its therapy. The varied and contradictory experience of different workers further confounds the clinicians involved in the care of these patients. Selection of an appropriate and customized treatment schedule is a discretion the treating clinician has to make.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D003622 Dapsone A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) Diaminodiphenylsulfone,Sulfonyldianiline,4,4'-Diaminophenyl Sulfone,Avlosulfone,DADPS,Dapsoderm-X,Dapson-Fatol,Diaphenylsulfone,Disulone,Sulfona,4,4' Diaminophenyl Sulfone,Sulfone, 4,4'-Diaminophenyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000965 Antimony A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D016773 Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes. Leishmaniasis, American,Leishmaniasis, New World,Leishmaniasis, Old World,Oriental Sore,American Leishmaniasis,Cutaneous Leishmaniases,Cutaneous Leishmaniasis,Leishmaniases, Cutaneous,New World Leishmaniasis,Old World Leishmaniasis,Sore, Oriental

Related Publications

Vikram K Mahajan, and Nand Lal Sharma
June 2005, Medecine et maladies infectieuses,
Vikram K Mahajan, and Nand Lal Sharma
November 2013, Drugs,
Vikram K Mahajan, and Nand Lal Sharma
April 2015, The British journal of dermatology,
Vikram K Mahajan, and Nand Lal Sharma
August 2003, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
Vikram K Mahajan, and Nand Lal Sharma
March 2022, Clinical and experimental dermatology,
Vikram K Mahajan, and Nand Lal Sharma
September 2021, Rheumatology (Oxford, England),
Vikram K Mahajan, and Nand Lal Sharma
November 2007, Expert opinion on pharmacotherapy,
Vikram K Mahajan, and Nand Lal Sharma
December 2004, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Vikram K Mahajan, and Nand Lal Sharma
January 2006, American journal of clinical dermatology,
Copied contents to your clipboard!